Eni Halilaj, assistant professor of mechanical engineering and biomedical engineering, is presenting a new seminar series sponsored by the Center for Machine Learning and Health (CMLH). These talks from academic and industry leaders will bring together researchers across campus and stimulate timely conversation around digital health and our community’s role in the future of healthcare.
The mission of the CMLH is to promote novel digital health technology that rethinks and reinvents paths to wellness, healthcare delivery, and healthcare infrastructure. The CMLH is a technology agnostic (not just machine learning!), university-level center whose participation in is open to the entire University. For more information, please visit the CMLH and PHDA websites at https://www.cs.cmu.edu/cmlh-cfp and https://healthdataalliance.com/ or find us on Twitter @HealthDataCMU.
The Zoom link is below. Meeting ID: 935 3548 8696. Passcode: 762743.
Kate Rosenbluth, PhD, is the founder of Cala Health, a bioelectronic medicines company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology. Prior to founding Cala, she developed cutting-edge neurotherapies with Brainlab, Autonomic Technologies, and Genentech, and completed a postdoctoral fellowship at UCSF in Neurosurgery following her Ph.D. in bioengineering at UC Berkeley and UCSF. Rosenbluth has authored more than 60 patents and peer-reviewed publications. She is a perpetual student and committed educator in innovation leadership and healthcare. She currently serves on the McKinsey Women’s Executive Roundtable and the Strategy Group of the Center for Healthcare Innovation.
>Kate Rosenbluth, founder and Chief Scientific officer at Cala Health, will talk about building an award-winning wearable bioelectronic medicine company headquartered in the San Francisco Bay area. The company’s wearable neuromodulation therapies utilize electricity as medicine, merging innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, with a vertically integrated commercial model for direct delivery of its prescription therapies. The company recently launched its first product, Cala Trio™, a non-invasive, wrist-worn prescription therapy for essential tremor. Cala Health has new therapies under development in neurology, cardiology, and mental health, and is backed by leading investors in both healthcare and technology.